树突状细胞与细胞因子诱导的杀伤细胞免疫治疗对恶性肿瘤化疗后患者免疫功能的影响  

Effect of DC and CIK Cell on the Immune Function of Cancer Patients After Chemotherapy

作　　者：陈冬波[1] 张世强[1] 王保庆[1] 张兰胜[1] 王自全[1] 

机构地区：[1]徐州医学院第二附属肿瘤内科,江苏徐州221006

出　　处：《国际检验医学杂志》2011年第5期571-572,575,共3页International Journal of Laboratory Medicine

摘　　要：目的探讨树突状细胞(DC)与细胞因子诱导的杀伤细胞(CIK)治疗对化疗后肿瘤患者免疫功能的影响。方法采集化疗后恶性肿瘤患者外周血单个核细胞,经体外诱导产生DC和CIK细胞,每个患者接受DC与CIK细胞治疗至少2个疗程;采用流式细胞术检测21例健康者和48例肿瘤患者化疗前后及DC联合CIK治疗后外周血淋巴细胞CD3+、CD4+、CD8+、NK细胞及CD4+/CD8+比值。结果肿瘤患者外周血CD3+、CD4+、CD8+、CD4+/CD8+及NK细胞数量低于健康对照组,差异具有统计学意义(P<0.05);化疗后外周血CD3+、CD4+、NK细胞及CD4+/CD8+比值较化疗前降低,差异均有统计学意义(P<0.05),但化疗前后CD8+均值变化无统计学意义(P>0.05)。DC与CIK细胞回输后外周血CD3+、CD4+、CD4+/CD8+及NK细胞均高于回输前,CD8+低于回输前,但CD3+、CD4+仍低于健康对照组,差异具有统计学意义(P<0.05)。结论恶性肿瘤患者化疗后免疫力降低,应用DC与CIK细胞免疫治疗,可提高恶性肿瘤患者的免疫功能。Objective To explore the effect of dendritic cell （DC） and cytokine inducing killer （CIK） cell treatment on the immune function of cancer patients after chemotherapy. Methods DC and CIK were prepared from peripheral blood mononuclear cells of cancer patients;to detect the mean values of CD3 ^＋ , CD4 ^＋ ,CD8 ^＋ , NK cell and CD4^＋/CD8^＋ ratio by flow cytometry in 21 healthy controls 48 cancer patients. Results Compared with healthy control group, the mean values of CD3^＋ ,CD4^＋ ,CD8^＋ , NK cell and CD4^＋ /CD8 ^＋ ratio in cancer patients significantly decreased（P〈0. 05）;The mean values of CD3^＋ , CD4^＋ , NK cell and CD4^＋/ CD8^＋ ratio more significantly decreased than those in patients after chemotherapy （P〈0. 05） ,the mean CD8^＋ values remained stable （P〈0.05）. but after treatment with DC and CIK cell,The mean values of CD3^＋ ,CD4^＋ ,NK cell and CD4^＋ /CD8^＋ were significantly higher than that after chemotherapy, the CD8^＋ was significantly lower than that after chemotherapy,and the CD3^＋ ,CD4^＋ was still significantly lower than that of healthy controls（P〈0.05）. Conclusion Chemotherapy may inhibit the immunological response of cancer patients. And the use of DC and CIK cell can improve the patients＇immune function after chemotherapy.

关 键 词：细胞因子诱导的杀伤细胞 树突状细胞 细胞 培养的 免疫疗法 肿瘤 

分 类 号：R730.53[医药卫生—肿瘤]